Marinus Pharmaceuticals Inc (MRNS)
1.205
0.00 (0.00%)
USD |
NASDAQ |
Jul 05, 15:15
Marinus Pharmaceuticals SG&A Expense (Annual): 61.15M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 61.15M |
| December 31, 2022 | 56.84M |
| December 31, 2021 | 37.28M |
| December 31, 2020 | 18.55M |
| December 31, 2019 | 11.46M |
| December 31, 2018 | 8.785M |
| Date | Value |
|---|---|
| December 31, 2017 | 6.667M |
| December 31, 2016 | 6.237M |
| December 31, 2015 | 5.516M |
| December 31, 2014 | 3.23M |
| December 31, 2013 | 1.229M |
| December 31, 2012 | 0.6851M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
11.46M
Minimum
2019
61.15M
Maximum
2023
37.06M
Average
37.28M
Median
2021
SG&A Expense (Annual) Benchmarks
| Arcutis Biotherapeutics Inc | 185.14M |
| Heron Therapeutics Inc | 116.66M |
| Pfizer Inc | 14.77B |
| Gritstone Bio Inc | 28.78M |
| Actinium Pharmaceuticals Inc | 13.33M |